Do you want to read an article? Please log in or register.
DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis
Genitourinary Cancer
Related content
Genitourinary Cancer
Efficacy and Safety of Enzalutamide and Abiraterone Plus Prednisolone in Elder Castration-Resistant Prostate Cancer Patients: A Sub-Analysis From the ENABLE Study
Prostate
Okamura T, Izumi K, Kurokawa S, Shima T, Kato Y, Mita K, Kamiyama M, Inoue S, Hoshi S, Tanaka N, Yoshio Y, Enokida H, Chikazawa I, Kawai N, Hashimoto K, Fukagai T, Shigehara K, Takahara S, Mizokami A
doi: 10.1002/pros.24897
Genitourinary Cancer
(177)Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 study
Eur J Cancer
Mandel P, Groener D, Follacchio G, Ürün Y, Bourlon MT, Sabet A, Grünwald F, Tural D, Büttner T, Kopp RM, Taha T, Chun FK, Facchini G, Myint ZW, Seront E, Conteduca V, Quiroga MNG, Aurilio G, Palacios GA, Bögemann M, Roviello G, Matrana MR, Sammarco E, Laguado MIZ, Galli L, Ansari J, Danielli L, Molina-Cerrillo J, Rescigno P, Yazgan SC, Bastos DA, Jazieh AR, Monteiro FSM, Soares A, Massari F, Wenzel M, Capoccetti F, Santoni M
doi: 10.1016/j.ejca.2025.115789
Genitourinary Cancer
Efficacy and Feasibility of Cabazitaxel for Very Elderly Patients of ≥ 80 Years of Age With Metastatic Castration-Resistant Prostate Cancer: A Real-World Multi-Intuitional Analysis
Prostate
Suzuki K, Hirata J, Okamura Y, Bando Y, Hara T, Terakawa T, Hyodo Y, Chiba K, Teishima J, Miyake H
doi: 10.1002/pros.24889
Genitourinary Cancer
Efficacy outcomes 12 months after initiation of darolutamide in non-metastatic castrate resistant prostate cancer (nmCRPC) from the real world UK multi-centre RECORD study
J Clin Oncol
Challapalli A, Bahl A, Randhawa M, Omi Parikh, Sundar S, Birtle AJ, Malik J, Mark Prentice, Muthukumar D, Bhana R, Jayaprakash KT, Syndikus I, Mitra A, Elumalai T, Gray E, Glen H, Beresford M, Khoo V, Foulstone E, White P
doi: 10.1200/JCO.2025.43.5_suppl.83
Genitourinary Cancer
Time to Castration Resistance is Associated With Overall Survival Even After the Achievement of Castration Resistance in Metastatic Prostate Cancer
Prostate
Kato H, Goto Y, Kojima S, Onoda Y, Wakai K, Hou K, Araki K, Sakamoto S, Ichikawa T, Naya Y
doi: 10.1002/pros.24850
CHICAGO 2025
Genitourinary Cancer
PSMA-delay castration: 177Lu-PSMA-617 versus observation in patients with PSMA-positive oligometastatic prostate cancer
COMMENTED
Genitourinary Cancer
Effects of Enzalutamide on the Sexual Activity of Patients with Biochemically Recurrent Prostate Cancer: A Post Hoc Analysis of Patient-reported Outcomes in the EMBARK Study
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
Eur Urol
Freedland SJ, Mulhall JP, Gleave M, Giorgi U, Saad F, Rannikko A, Ivanova JI, Nasr AF, Reisman AL, Ganguli A, Kral P, Turnbull J, Shore N
doi: 10.1016/j.eururo.2025.02.006
Genitourinary Cancer
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial
Lancet Oncol
Matsubara N, Azad AA, Agarwal N, Saad F, De Giorgi U, Joung JY, Fong PCC, Jones RJ, Zschäbitz S, Oldenburg J, Shore ND, Dunshee C, Carles J, Fay AP, Cislo P, Chang J, Healy CG, Niyazov A, Fizazi K
doi: 10.1016/S1470-2045(25)00030-0
COMMENTED
Genitourinary Cancer
Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
J Clin Oncol
Garje R, Riaz IB, Naqvi SAA, Rumble RB, Taplin ME, Kungel TM, Herchenhorn D, Zhang T, Beckermann KE, Vapiwala N, Carducci MA, Celano P, Hotte SJ, Basu A, Borno H, Bryce AH, Wang P, Wulff-Burchfield E, Bodei L, Loblaw A, Hamilton RJ, Emamekhoo H, Hope TA, He H, Murad MH, Liu H, Williams JE Jr, Parikh RA
doi: 10.1200/JCO-25-00007